MF
RYTM icon

Manchester Financial’s Rhythm Pharmaceuticals RYTM Stock Holding History

Manchester Financial’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,100
Closed -$33K – 762
2020
Q4 		$33K Buy
+1,100
New +$28K 0.02% 204

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Manchester Financial's RYTM Position: Q1 2021 in Review

Manchester Financial sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2021, closing a stake of 1,100 shares — an estimated $33K sold.

Manchester Financial first reported a position in RYTM in Q4 2020 and held it in 1 quarter. The position peaked at $33K in Q4 2020. 124 funds tracked by Wall St. Rank hold RYTM as of Q1 2021.

  • Manchester Financial reported no remaining Rhythm Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Manchester Financial sold 1,100 Rhythm Pharmaceuticals shares in Q1 2021, an estimated $33K.
  • Manchester Financial first reported a position in Rhythm Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Manchester Financial's Rhythm Pharmaceuticals position peaked at $33K in Q4 2020.
  • 124 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2021.

Based on Manchester Financial's 13F filing for Q1 2021, filed 3 May 2021.